Venlafaxine versus mirtazapine in the treatment of undifferentiated somatoform disorder: A 12-week prospective, open-label, randomized, parallel-group trial

Clinical Drug Investigation

Volumn 28, Issue 4, 2008, Pages 251-261

  Han, Changsu ^a,b   Pae, Chi Un ^b,c   Lee, Bun Hee ^a   Ko, Young Hoon ^a   Masand, Prakash S ^a   Patkar, Ashwin A ^a   Joe, Sook Haeng ^a   Jung, In Kwa ^a  

^a Korea University College of Medicine   (South Korea)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c The Catholic University of Korea   (South Korea)

Author keywords

Mirtazapine, therapeutic use; Somatoform disorders; Venlafaxine, therapeutic use

Indexed keywords

MIRTAZAPINE; VENLAFAXINE;

ANOREXIA; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMATOFORM DISORDER; SOMNOLENCE; SWEATING; VOMITING; XEROSTOMIA; YAWNING;

ADULT; ANTIDEPRESSIVE AGENTS; CYCLOHEXANOLS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISORDERS OF EXCESSIVE SOMNOLENCE; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; NAUSEA; PATIENT DROPOUTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; SOMATOFORM DISORDERS; TIME FACTORS; TREATMENT OUTCOME; XEROSTOMIA; YAWNING;

EID: 40949123518     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828040-00006     Document Type: Article

References (57)

1. Schappert SM. National ambulatory medical care survey: 1989 summary. Vital Health Stat 13; 1992 Apr (110): 1-80
2. Hartz AJ, Noyes R, Bentler SE, et al. Unexplained symptoms in primary care: perspectives of doctors and patients. Gen Hosp Psychiatry 2000 May-Jun; 22 (3): 144-52
3. de Waal MW, Arnold IA, Eekhof JA, et al. Somatoform disorders in general practice: prevalence, functional impairment and comorbidity with anxiety and depressive disorders. Br J Psychiatry 2004 Jun; 184: 470-6
4. Khan AA, Khan A, Harezlak J, et al. Somatic symptoms in primary care: etiology and outcome. Psychosomatics 2003 Nov-Dec; 44 (6): 471-8
5. Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003; 12 (1): 34-43
6. Simon GE, VonKorff M, Piccinelli M, et al. An international study of the relation between somatic symptoms and depression. N Engl J Med 1999 Oct 28; 341 (18): 1329-35
7. Wells KB, Rogers W, Burnam A, et al. How the medical comorbidity of depressed patients differs across health care settings: results from the Medical Outcomes Study. Am J Psychiatry 1991 Dec; 148 (12): 1688-96
8. Beekman AT, Penninx BW, Deeg DJ, et al. Depression and physical health in later life: results from the Longitudinal Aging Study Amsterdam (LASA). J Affect Disord 1997 Dec; 46 (3): 219-31
9. Bair MJ, Robinson RL, Eckert GJ, et al. Impact of pain on depression treatment response in primary care. Psychosom Med 2004 Jan-Feb; 66 (1): 17-22
10. Katon W, Lin E, Von Korff M, et al. Somatization: a spectrum of severity. Am J Psychiatry 1991 Jan; 148 (1): 34-40
11. Smith Jr GR, Monson RA, Ray DC. Patients with multiple unexplained symptoms: their characteristics, functional health, and health care utilization. Arch Intern Med 1986 Jan; 146 (1): 69-72
12. Farabaugh A, Mischoulon D, Fava M, et al. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients. Int Clin Psychopharmacol 2005 Mar; 20 (2): 87-91
13. Terre L, Poston WS, Foreyt J, et al. Do somatic complaints predict subsequent symptoms of depression? Psychother Psychosom 2003 Sep-Oct; 72 (5): 261-7
14. Smith D, Dempster C, Glanville J, et al. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002 May; 180: 396-404
15. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001 Mar; 178: 234-41
16. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001 Jul; 179: 15-22
17. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 Feb; 62 (2): 190-8
18. Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005 Feb; 66 (2): 238-47
19. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J Clin Psychopharmacol 2004 Oct; 24 (5): 488-96
20. Rynn MA, Riddle MA, Yeung PP, et al. Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials. Am J Psychiatry 2007 Feb; 164 (2): 290-300
21. Sheehan DV. Venlafaxine extended release (XR) in the treatment of generalized anxiety disorder. J Clin Psychiatry 1999; 60 Suppl. 22: 23-8
22. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004 Aug; 19 (6): 387-96
23. Bradwejn J, Ahokas A, Stein DJ, et al. Venlafaxine extended release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005 Oct; 187: 352-9
24. Pollack MH, Lepola U, Koponen H, et al. A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 2007; 24 (1): 1-14
25. Pollack MH, Worthington 3rd JJ, Otto MW, et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 1996; 32 (4): 667-70
26. Davidson J, Baldwin D, Stein DJ, et al. Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 2006 Oct; 63 (10): 1158-65
27. Davidson J, Rothbaum BO, Tucker P, et al. Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 2006 Jun; 26 (3): 259-67
28. Bradley RH, Barkin RL, Jerome J, et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003 Sep-Oct; 10 (5): 318-23
29. Forssell H, Tasmuth T, Tenovuo O, et al. Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J Orofac Pain 2004; 18 (2): 131-7
30. Galvez R, Caballero J, Atero M, et al. Venlafaxine extended release for the treatment of chronic pain: a series of 50 cases [in Spanish]. Actas Esp Psiquiatr 2004 Mar-Apr; 32 (2): 92-7
31. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004 May; 24 (5): 621-9
32. Pernia A, Mico JA, Calderon E, et al. Venlafaxine for the treatment of neuropathic pain. J Pain Symptom Manage 2000 Jun; 19 (6): 408-10
33. Kroenke K, Messina 3rd N, Benattia I, et al. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. J Clin Psychiatry 2006 Jan; 67 (1): 72-80
34. Freynhagen R, Muth-Selbach U, Lipfert P, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Curr Med Res Opin 2006 Feb; 22 (2): 257-64
35. Kuiken TA, Schechtman L, Harden RN. Phantom limb pain treatment with mirtazapine: a case series. Pain Pract 2005 Dec; 5 (4): 356-60
36. Theobald DE, Kirsh KL, Holtsclaw E, et al. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage 2002 May; 23 (5): 442-7
37. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002 Mar-Apr; 64 (2): 258-66
38. Association AP. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press 1994
39. Beck AT, Steer RA. Manual for the Beck Depression Inventory. San Antonio (TX): Psychological Corporation 1993
40. Goldberg D. General Health Questionnaire (GHQ-12). Windsor: NFER-Nelson 1992
41. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002 Sep-Oct; 10 (5): 541-50
42. Silverstone PH, Salinas E. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 2001 Jul; 62 (7): 523-9
43. Arnold LM, Pritchett YL, D'Souza DN, et al. Duloxetine for the treatment of fibromyalgia in women: pooled results from two randomized, placebo-controlled clinical trials. J Womens Health (Larchmt) 2007 Oct; 16 (8): 1145-56
44. Vitton O, Gendreau M, Gendreau J, et al. A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia. Hum Psychopharmacol 2004 Oct; 19 Suppl. 1: S27-35
45. Greco T, Eckert G, Kroenke K. The outcome of physical symptoms with treatment of depression. J Gen Intern Med 2004 Aug; 19 (8): 813-8
46. Kroenke K. Somatoform disorders and recent diagnostic controversies. Psychiatr Clin North Am 2007 Dec; 30 (4): 593-619
47. Escobar JI, Gara MA, Diaz-Martinez AM, et al. Effectiveness of a time-limited cognitive behavior therapy type intervention among primary care patients with medically unexplained symptoms. Ann Fam Med 2007 Jul-Aug; 5 (4): 328-35
48. O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000 Sep; 15 (9): 659-66
49. Panerai AE, Monza G, Movilia P, et al. A randomized, within-patient, cross-over, placebo-controlled trial on the efficacy and tolerability of the tricyclic antidepressants chlorimipramine and nortriptyline in central pain. Acta Neurol Scand 1990 Jul; 82 (1): 34-8
50. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a metaanalysis of 39 placebo-controlled studies. Pain 1992 May; 49 (2): 205-19
51. Jackson JL, O'Malley PG, Kroenke K. Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectr 2006 Mar; 11 (3): 212-22
52. O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999 Dec; 48 (12): 980-90
53. de Vasconcelos Cunha UG, Lopes Rocha F, Avila de Melo R, et al. A placebo-controlled double-blind randomized study of venlafaxine in the treatment of depression in dementia. Dement Geriatr Cogn Disord 2007 May 10; 24 (1): 36-41
54. Rudolph RL, Fabre LF, Feighner JP, et al. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry 1998 Mar; 59 (3): 116-22
55. Samuelian JC, Hackett D. A randomized, double-blind, parallelgroup comparison of venlafaxine and clomipramine in outpatients with major depression. J Psychopharmacol 1998; 12 (3): 273-8
56. Hong CJ, Hu WH, Chen CC, et al. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003 Aug; 64 (8): 921-6
57. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999 Nov; 14 (6): 329-37